Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human PCSK9 Monoclonal Antibody, Endotoxin 0.05 EU/mg

Catalog No.: YR0155

Basic Information

Molecular Weight
150 kDa

Endotoxin
<0.05EU/mg (<0.00005EU/μg)
Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9-mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab.

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical P K and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Evolocumab Biosimilar

Isotype
Human IgG2 lambda

Immunogen
Human PCSK9

RecommendedIsotype Control(s)

Recommended Dilution Buffer
1×PBS pH 7.4

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Product Information

Production
Purified from cell culture supernatant in an animal-free facility

Purification
Protein A or G purification

Storage
Store at -20℃